Representatives from the company will ring the bell at 09:00 AM and will then give a short presentation of the company. The presentation starts at 09:10 AM at Oslo Børs and is open to the press and public.
Serodus ASA will be listed on Oslo Børsunder the ticker SER.
Serodus ASA is a Norwegian biopharmaceutical company dedicated to the development of compounds for the treatment of patients with cardiovascular diseases with unmet clinical needs. The company was founded based on a discovery from the University of Oslo. The initial product pipeline focuses on the following two diseases: SER 100 – Isolated Systolic Hypertension (ISH) – reducing the systolic blood pressure with only minor effect on diastolic pressure and SER 102 – Prevention of Atrial Fibrillation (AF) during intra-thoracical surgery.
The SER100 candidate is in clinical development and ready for phase II Proof-of-Concept studies. The other drug candidate is in pre-clinical phase. The product pipeline addresses large markets with substantial unmet clinical needs.